A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Colorado Cancer Research -
Location
-
Principal Investigator
Lawrence Karsh -
Sponsor
Pfizer Inc
Enrollment Form
This study is currently enrolling.